Trade Bionano Genomics, Inc. - BNGO CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.0444
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022262 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02226%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00004 %($0.01)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00004%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022262 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00004 %
  ($0.01)

Key Stats

• Prev. Close: 1.6279
• Open: 1.6279
• 1-Year Change: -1.87%
• Day's Range: 1.6279 - 1.6878

Trade Bionano Genomics, Inc. - BNGO

Bionano Genomics (BNGO) is a provider of solutions for genome analysis. Additionally, the company offers diagnostic services, software and optical genome mapping solutions for basic, translational and clinical research applications.

Based in San Diego, California, the company has two businesses: Lineagen and BioDiscovery.

Lineagen provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental impairments.

Through BioDiscovery, the company also offers an industry-leading, platform-diagnostic software solution. Integrating next-generation sequencing and microarray data to analyse, visualise, interpret, and report copy number variants, single-nucleotide variants, and the absence of heterozygosity across the genome in a single consolidated view. 

In October 2021, Bionano Genomics bought Biodiscovery, a software company that provides solutions for analysing, interpreting and reporting genomics data.

The acquisition is expected to accelerate the adoption of optical genome mapping (OGM), with the integration of BioDiscovery's NxClinical software solution. Saphyr System is Bionano’s featured product for OGM.

Saphyr is an ultra-sensitive genome analysis platform that can detect structural variations for mosaic samples or heterogeneous cancer samples with a false positive rate of less than 2%.

The company, founded in 2003, sells its products for research use in laboratories associated with academic and governmental research institutions. For North America and Europe, Bionano sells its products through a direct sales force. It also sells its products via third party distributors in China, Japan, South Korea, Singapore, Australia, India and South Africa. 

Bionano became a public company in September 2018. Its shares are traded on the Nasdaq under the ticker symbol BNGO.